Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis
Status:
Completed
Trial end date:
2019-11-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine wether cobimetinib + vemurafenib combination
treatment is effective in the treatment of BRAFV600-mutated melanoma patients with brain
metastasis